Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PTC Advances Cystic Fibrosis Candidate On Encouraging Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Company is pursuing PTC124 in nonsense-mutation-mediated CF, a patient population of about 3,000 in the U.S.
Advertisement

Related Content

PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
PTC Fully Enrolls Duchenne MD Trial; Expects Top-Line Data In Early 2010
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate
PTC Taps Genzyme’s Global Reach, Pocketbook In Ultra-orphan Licensing Deal
Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease
Vertex Advance In Cystic Fibrosis May Treat The Underlying Disease

Topics

Advertisement
UsernamePublicRestriction

Register

PS067903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel